Mahamaya Lifesciences (BOM:544611) EBIT: ₹168 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544611 Mahamaya Lifesciences Ltd BOM:544611
16 GF Score
Price ₹166.45
! 4 Warning Signs
View Full Analysis

What is Mahamaya Lifesciences EBIT?

Mahamaya Lifesciences BOM:544611 16 EBIT is ₹168 Mil as of Mar. 2026. GuruFocus rates BOM:544611 with a GF Score™ of 16/100. The stock has 4 warning signs investors should review.

Mahamaya Lifesciences's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹168 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹168 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mahamaya Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 was 13.43%. Mahamaya Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 27.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mahamaya Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.80%.

Mahamaya Lifesciences  (BOM:544611) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mahamaya Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=324.752 * ( 1 - 34.58% )/( (1098.632 + 2064.398)/ 2 )
=212.4527584/1581.515
=13.43 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1883.521 - 744.941 - ( 39.948 - max(0, 1316.216 - 1567.306+39.948))
=1098.632

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3102.802 - 644.414 - ( 393.99 - max(0, 1831.338 - 2664.457+393.99))
=2064.398

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Mahamaya Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=335.076/( ( (217.395 + max(728.478, 0)) + (288.267 + max(1165.867, 0)) )/ 2 )
=335.076/( ( 945.873 + 1454.134 )/ 2 )
=335.076/1200.0035
=27.92 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(484.629 + 1002.076 + 38.448) - (744.941 + 0 + 51.734)
=728.478

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(707.599 + 1410.526 + 7.3929999999996) - (644.414 + 0 + 315.237)
=1165.867

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mahamaya Lifesciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=167.538/4409.140
=3.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mahamaya Lifesciences EBIT Related Terms

Mahamaya Lifesciences EBIT Historical Data

* Premium members only.

The historical data trend for Mahamaya Lifesciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mahamaya Lifesciences EBIT Chart

Mahamaya Lifesciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
50.27 76.42 118.78 240.60 320.16

Mahamaya Lifesciences Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Mar26
EBIT Get a 7-Day Free Trial 0.00 0.00 128.49 112.11 167.54

BOM:544611 vs CTVA, CF, MOS: EBIT Comparison

For the Agricultural Inputs subindustry, Mahamaya Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mahamaya Lifesciences EV-to-EBIT vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Mahamaya Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mahamaya Lifesciences's EV-to-EBIT falls into.


BOM:544611
16GF Score
Mahamaya Lifesciences Ltd BOM:544611
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mahamaya Lifesciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹168 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹168 Mil mean?
Mahamaya Lifesciences (BOM:544611) has a EBIT of ₹168 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mahamaya Lifesciences.
Is Mahamaya Lifesciences' EBIT too high?
Mahamaya Lifesciences' current EBIT is ₹168 Mil. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' EBIT compare to CTVA and CF?
Mahamaya Lifesciences' EBIT of ₹168 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for an Agriculture company?
A good EBIT depends on the Agriculture industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mahamaya Lifesciences. Mahamaya Lifesciences's current EBIT is ₹168 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current EBIT of ₹168 Mil. The current EBIT is ₹168 Mil. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current EBIT is ₹168 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mahamaya Lifesciences Business Description

Address Sohna Road, Sector-49, Unit No. 369, 370, 370A & 370B, 3rd Floor, Prime Tower-B1, Spaze ITech Park, Gurugram, HR, IND, 122018
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score

Get the complete analysis for BOM:544611

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹166.45
Price